Zappia M - Search Results

1

Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.

Zappia M, Quattrone A. Zappia M, et al. Neurology. 2002 Dec 24;59(12):2010; author reply 2010. doi: 10.1212/wnl.59.12.2010-a. Neurology. 2002. PMID: 12499509 No abstract available.

2

Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD.

Zappia M, Annesi G, Quattrone A. Zappia M, et al. Neurology. 2002 Mar 12;58(5):837; author reply 837-8. doi: 10.1212/wnl.58.5.837-a. Neurology. 2002. PMID: 11889264 No abstract available.

3

Body weight influences pharmacokinetics of levodopa in Parkinson's disease.

Zappia M, Crescibene L, Arabia G, Nicoletti G, Bagalà A, Bastone L, Caracciolo M, Bonavita S, Di Costanzo A, Scornaienchi M, Gambardella A, Quattrone A. Zappia M, et al. Clin Neuropharmacol. 2002 Mar-Apr;25(2):79-82. doi: 10.1097/00002826-200203000-00004. Clin Neuropharmacol. 2002. PMID: 11981233

4

Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.

Nicoletti A, Mostile G, Nicoletti G, Arabia G, Iliceto G, Lamberti P, Marconi R, Morgante L, Barone P, Quattrone A, Zappia M. Nicoletti A, et al. Among authors: zappia m. J Neurol. 2016 May;263(5):888-894. doi: 10.1007/s00415-016-8075-6. Epub 2016 Mar 10. J Neurol. 2016. PMID: 26964541

5

Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.

Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D, Pugliese P, Spadafora P, Tarantino P, Carrideo S, Civitelli D, De Marco EV, Cirò-Candiano IC, Gambardella A, Quattrone A. Zappia M, et al. Arch Neurol. 2005 Apr;62(4):601-5. doi: 10.1001/archneur.62.4.601. Arch Neurol. 2005. PMID: 15824260 Clinical Trial.

6

Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa?

Zappia M, Quattrone A. Zappia M, et al. Mov Disord. 2008 May 15;23(7):1062-1063. doi: 10.1002/mds.21819. Mov Disord. 2008. PMID: 17994584 No abstract available.

7

Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms.

Zappia M, Manna I, Serra P, Cittadella R, Andreoli V, La Russa A, Annesi F, Spadafora P, Romeo N, Nicoletti G, Messina D, Gambardella A, Quattrone A. Zappia M, et al. Arch Neurol. 2004 Mar;61(3):341-4. doi: 10.1001/archneur.61.3.341. Arch Neurol. 2004. PMID: 15023809

8

Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy.

Nicoletti G, Lodi R, Condino F, Tonon C, Fera F, Malucelli E, Manners D, Zappia M, Morgante L, Barone P, Barbiroli B, Quattrone A. Nicoletti G, et al. Among authors: zappia m. Brain. 2006 Oct;129(Pt 10):2679-87. doi: 10.1093/brain/awl166. Epub 2006 Jun 30. Brain. 2006. PMID: 16815875

9

Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: a crossover trial.

Nicoletti A, Arabia G, Pugliese P, Nicoletti G, Torchia G, Condino F, Morgante L, Quattrone A, Zappia M. Nicoletti A, et al. Among authors: zappia m. Clin Neuropharmacol. 2007 Sep-Oct;30(5):276-80. doi: 10.1097/wnf.0b013e318050c9f9. Clin Neuropharmacol. 2007. PMID: 17909305 Clinical Trial.

10

Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.

Fera F, Nicoletti G, Cerasa A, Romeo N, Gallo O, Gioia MC, Arabia G, Pugliese P, Zappia M, Quattrone A. Fera F, et al. Among authors: zappia m. Brain Res Bull. 2007 Sep 14;74(1-3):75-83. doi: 10.1016/j.brainresbull.2007.05.009. Epub 2007 Jun 6. Brain Res Bull. 2007. PMID: 17683792

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

529 results

Search Page

Filters